Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.

EMBO molecular medicine - 1 Jun 2012

Williamson Chris T, Kubota Eiji, Hamill Jeffrey D, Klimowicz Alexander, Ye Ruiqiong, Muzik Huong, Dean Michelle, Tu LiRen, Gilley David, Magliocco Anthony M, McKay Bruce C, Bebb D Gwyn, Lees-Miller Susan P

Abstract excerpt

Poly-ADP ribose polymerase (PARP) inhibitors have shown promise in the treatment of human malignancies characterized by deficiencies in the DNA damage repair proteins BRCA1 and BRCA2 and preclinical studies have demonstrated the potential effectiveness of PARP inhibitors in targeting ataxia-telangiectasia mutated (ATM)-deficient tumours. Here, we show that mantle cell lymphoma (MCL) cells deficient in both ATM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Lymphoma, Mantle-Cell

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 22416035
DOI: 10.1002/emmm.201200229
PMCID: PMC3443945

Genes

ATM
BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.PMID 22416035Read ↗

ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 InhibitorsSemantic proximity Read ↗

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.Semantic proximity Read ↗

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor OlaparibSemantic proximity Read ↗

Novel agents for mantle cell lymphoma: molecular rational and clinical data.Semantic proximity Read ↗

ATM-Deficient Cancers Provide New Opportunities for Precision OncologySemantic proximity Read ↗

A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphomaSemantic proximity Read ↗

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cellsSemantic proximity Read ↗

A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.Semantic proximity Read ↗

ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma.Semantic proximity Read ↗

Targeting homologous recombination repair in BCR/ABL1-positive cells using PARP inhibitorSemantic proximity Read ↗

PARP1 expression, activity andex vivosensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemiaSemantic proximity Read ↗

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.